Cryoport Inc
CYRX
View Detailed Chart
8.770USD
+0.130+1.50%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
440.94MMarket Cap
6.55P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.50%
5 Days
-12.65%
1 Month
+1.86%
6 Months
+36.82%
Year to Date
+12.72%
1 Year
+5.03%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-15Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
12.111
Target Price
+40.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Company’s supply chain solutions enable manufacturers, contract manufacturers (CDMO’s), contract research organizations (CRO’s), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 170.79.
Fairly Valued
The company’s latest PB is 0.92, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.37M shares, decreasing 22.35% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.79M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.90.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Company’s supply chain solutions enable manufacturers, contract manufacturers (CDMO’s), contract research organizations (CRO’s), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
Ticker SymbolCYRX
CompanyCryoport Inc
CEOMr. Jerrell Wilson (Jerry) Shelton
Websitehttps://www.cryoport.com/
Related Instruments
-0.39%
-1.68%
+0.54%
+1.10%
-0.57%
+2.25%
+3.87%
+9.11%
+5.52%
+0.33%
+2.61%
-1.17%
-2.33%
-6.54%
+0.60%
+4.63%
-2.97%
-5.61%
-2.05%
-1.75%
